Beyond erectile dysfunction: Optimization of vardenafil dihydrochloride for hepatic encephalopathy prophylaxis using hybrid lipid polymeric nanoparticles formulation

dc.AffiliationOctober University for modern sciences and Arts MSA
dc.contributor.authorMarwa H.S. Dawoud
dc.contributor.authorHeba T. Elbalkiny
dc.contributor.authorYasmeen E.M. Gharib
dc.contributor.authorSara A.A. Fakkar
dc.contributor.authorRowaa Saber
dc.contributor.authorMarry E. Yanni
dc.contributor.authorMai A. Zaafan
dc.date.accessioned2025-04-17T15:33:44Z
dc.date.available2025-04-17T15:33:44Z
dc.date.issued2025-03-06
dc.descriptionSJR 2024 0.817 Q1 H-Index 89
dc.description.abstractVardenafil dihydrochloride (VD), a phosphodiesterase-5 (PDE5) is widely used to treat erectile dysfunction, but recent studies suggested its potential for other diseases such as hepatic encephalopathy. However, VD suffers poor solubility and oral bioavailability, and significant first-pass metabolism. This study aims to enhance the bioavailability of VD by employing two combined approaches: formulation of VD into hybrid lipid-polymeric nanoparticles (HLPNPs), and incorporating piperine, a known bioavailability enhancer, to investigate its potential in preventing hepatic encephalopathy. HLPNPs were developed using homogenization/ultrasonication technique, with a one-factor design testing chitosan, oleic acid, or sodium alginate as the helper polymers. Oleic acid showed the best results and was used to prepare the optimized formula (O1), which had a particle size of 128 ± 2.8 nm, a polydispersity index of 0.173 ± 0.07, an entrapment efficiency of 93 ± 1.8 %, and a zeta potential of − 32 ± 1.67 mV. O1 showed a sustained drug release profile, with approximately 70 % of VD released over 72 h. O2 was then prepared with the addition of piperine, resulting in a longer residence time of 717 min compared to O1 (94 min) in the pharmacokinetics study. O1 showed a twofold increase in the bioavailability compared to the unformulated VD while O2 exhibited a ninefold increase. The improvement was confirmed by the higher Cmax from 9 ng/mL for standard VD to 13 ng/mL and 22 ng/mL for O1 and O2, respectively. In hepatic encephalopathy-induced mice model, O2 showed promising efficacy, with significant improvements in liver enzymes, ammonia levels, hippocampal BDNF levels, cGMP levels, and hippocampal GluR1 and P-CREB levels. These findings suggest that combining VD into HLPNPs with piperine is an effective strategy to overcome its bioavailability limitations and enhance its therapeutic potential.
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=22204&tip=sid&clean=0
dc.identifier.citationDawoud, M. H., Elbalkiny, H. T., Gharib, Y. E., Fakkar, S. A., Saber, R., Yanni, M. E., & Zaafan, M. A. (2025b). Beyond Erectile Dysfunction: Optimization of Vardenafil Dihydrochloride for Hepatic Encephalopathy Prophylaxis using Hybrid Lipid Polymeric Nanoparticles Formulation. Journal of Drug Delivery Science and Technology, 106787. https://doi.org/10.1016/j.jddst.2025.106787
dc.identifier.doihttps://doi.org/10.1016/j.jddst.2025.106787
dc.identifier.otherhttps://doi.org/10.1016/j.jddst.2025.106787
dc.identifier.urihttps://repository.msa.edu.eg/handle/123456789/6384
dc.language.isoen_US
dc.publisherEditions de Sante
dc.relation.ispartofseriesJournal of Drug Delivery Science and Technology ; Volume 107 , May 2025 , Article number 106787
dc.subjectEnhanced bioavailability
dc.subjectHepatic encephalopathy
dc.subjectOptimization
dc.subjectRepurposing
dc.subjectVardenafil dihydrochloride
dc.titleBeyond erectile dysfunction: Optimization of vardenafil dihydrochloride for hepatic encephalopathy prophylaxis using hybrid lipid polymeric nanoparticles formulation
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1-s2.0-S177322472500190X-main.pdf
Size:
11.36 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
51 B
Format:
Item-specific license agreed upon to submission
Description: